<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="117857">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02152969</url>
  </required_header>
  <id_info>
    <org_study_id>YH22162-101</org_study_id>
    <nct_id>NCT02152969</nct_id>
  </id_info>
  <brief_title>Drug-drug Interaction Study (Telmisartan, Amlodipine, Chlorthalidone)</brief_title>
  <official_title>An Open-label, Multiple-dose, Two-arm Clinical Study to Evaluate the Drug-drug Interaction and Safety of Telmisartan, Amlodipine and/or Chlorthalidone in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuhan Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yuhan Corporation</source>
  <oversight_info>
    <authority>Korea: Ministry of Food and Drug Safety</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the Drug-Drug(telmisartan, amlodipine and/ or
      chlorthalidone) interaction and safety in healthy adult volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>AUCt ss, Cmax ss of telmisartan/amlodipine/chlorthalidone</measure>
    <time_frame>Totally 28points for 24 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmin ss, tmax ss, t1/2 of telmisartan/amlodipine/chlorthalidone</measure>
    <time_frame>Totally 28points for 24 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Part B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Arm to evaluate influence of Chlorthalidone on pharmacokinetics of amlodipine and telmisartan.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Arm to evaluate influence of amlodipine and telmisartan on pharmacokinetics of Chlorthalidone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan</intervention_name>
    <arm_group_label>Part B</arm_group_label>
    <arm_group_label>Part A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine</intervention_name>
    <arm_group_label>Part B</arm_group_label>
    <arm_group_label>Part A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlorthalidone</intervention_name>
    <arm_group_label>Part B</arm_group_label>
    <arm_group_label>Part A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participant who has a body weight that is ≥55kg(male) or ≥50kg(female) with ideal
             body weight of 80-120% (ideal body weight)

          2. Who has not suffered from clinically significant disease

          3. Provision of signed written informed consent

        Exclusion Criteria:

          1. History of and clinically significant disease psychiatric, or malignancy.

          2. A history of drug abuse or the presence of positive reactions to drugs that have
             abuse potential in urine screenings for drugs.

          3. Administration of other investigational products within 3 months prior to the first
             dosing.

          4. Administration of herbal medicine within 2 weeks or administration of ethical drugs
             within 2 weeks or administration of over-the-counter (OTC) drugs within 1 week prior
             to the first dosing of the investigational product (if the investigator (study
             doctor) determines that the person meets other criteria appropriately, the relevant
             person may participate in the study).

          5. Volunteers considered not eligible for the clinical trial by the investigator (study
             doctor) due to reasons including laboratory test results, ECGs, or vital signs.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dong Seok Yim</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Catholic University of Korea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seung Hoon Han</last_name>
    <phone>82-2-2258-7888</phone>
    <email>calm100@catholic.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Catholic University of Korea Seoul St.Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seunghoon Han</last_name>
      <phone>82-2-2258-7888</phone>
      <email>calm100@catholic.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 1, 2014</lastchanged_date>
  <firstreceived_date>May 29, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Chlorthalidone</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Benzoates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
